Related Experiment Video

Updated: Jun 17, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
16:07

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method

Published on: September 16, 2017

Novel TNF antagonists for the treatment of rheumatoid arthritis

Laisvyde Statkute1, Eric M Ruderman

  • 1Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA.

Expert Opinion on Investigational Drugs
|December 17, 2009
PubMed
Abstract

Insights

Two new TNF antagonists, certolizumab and golimumab, show comparable efficacy and safety to existing rheumatoid arthritis (RA) treatments. Current data do not indicate a clear clinical advantage for these new RA therapies.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Tumor Necrosis Factor (TNF) antagonists are standard care for rheumatoid arthritis (RA).
  • Recent US approvals of two new TNF antagonists necessitate understanding their efficacy and safety.
  • Clinicians require data to integrate these agents into RA treatment algorithms.

Purpose of the Study:

  • To review published clinical trial data on certolizumab and golimumab for RA treatment.
  • To compare the efficacy and safety of certolizumab and golimumab with existing RA therapies.
  • To discuss the role of these new agents within the broader context of RA treatment options.

Main Methods:

  • Literature search of published manuscripts through September 2009.
  • Inclusion of abstracts from major rheumatology meetings (ACR, EULAR) from 2007-2009.
  • Review focused on clinical trial data regarding efficacy and safety in RA.

Main Results:

  • Certolizumab and golimumab demonstrate comparable efficacy and safety profiles to established TNF antagonists.
  • The review examines the use of these agents across various RA disease stages.
  • Comparative analysis includes other TNF antagonists and biologic therapies for RA.

Conclusions:

  • Certolizumab and golimumab offer comparable efficacy and safety to existing TNF antagonists for RA.
  • While theoretically advantageous, current data do not support a distinct clinical superiority for these new agents.
  • Further research may clarify the unique benefits of certolizumab and golimumab in RA management.

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...